GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » EV-to-EBITDA

Acceleron Pharma (Acceleron Pharma) EV-to-EBITDA : -41.24 (As of May. 07, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Acceleron Pharma's enterprise value is $10,361.1 Mil. Acceleron Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 was $-251.3 Mil. Therefore, Acceleron Pharma's EV-to-EBITDA for today is -41.24.

The historical rank and industry rank for Acceleron Pharma's EV-to-EBITDA or its related term are showing as below:

XLRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.65   Med: -17.8   Max: 1.47
Current: -41.24

During the past 10 years, the highest EV-to-EBITDA of Acceleron Pharma was 1.47. The lowest was -68.65. And the median was -17.80.

XLRN's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.535 vs XLRN: -41.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-07), Acceleron Pharma's stock price is $178.75. Acceleron Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-4.210. Therefore, Acceleron Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Acceleron Pharma EV-to-EBITDA Historical Data

The historical data trend for Acceleron Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma EV-to-EBITDA Chart

Acceleron Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.98 -15.34 -14.28 -18.20 -42.21

Acceleron Pharma Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.86 -42.21 -43.08 -31.91 -39.60

Competitive Comparison of Acceleron Pharma's EV-to-EBITDA

For the Biotechnology subindustry, Acceleron Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acceleron Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acceleron Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Acceleron Pharma's EV-to-EBITDA falls into.



Acceleron Pharma EV-to-EBITDA Calculation

Acceleron Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=10361.149/-251.263
=-41.24

Acceleron Pharma's current Enterprise Value is $10,361.1 Mil.
Acceleron Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-251.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acceleron Pharma  (NAS:XLRN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Acceleron Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=178.75/-4.210
=At Loss

Acceleron Pharma's share price for today is $178.75.
Acceleron Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.210.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Acceleron Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Acceleron Pharma (Acceleron Pharma) Business Description

Traded in Other Exchanges
N/A
Address
128 Sidney Street, Cambridge, MA, USA, 02139
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Executives
Sujay Kango officer: EVP, Chief Commercial Officer 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin officer: SVP, CFO and Treasurer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness officer: SVP, General Counsel and Sec. C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable director, officer: CEO and President C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co 10 percent owner 430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik director C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139

Acceleron Pharma (Acceleron Pharma) Headlines

From GuruFocus

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

By Business Wire Business Wire 10-28-2021